Carl Sterritt Email & Phone Number

New Milton, Gb

Newcastle Upon Tyne, Tyne And Wear, Gb

NunaBio is a privately-owned specialist DNA synthesis and development company that makes custom DNA sequences that no one else can. The current pharmaceutical industry DNA production model is unable to keep up with the quantity, quality and complexity required for cutting-edge technologies. Synthetically produced DNA is therefore becoming an increasingly critical component for a wide range of emerging and established industries with global demand increasing rapidly.Our multi-patented technology produces synthetic DNA using enzymes rather than hazardous chemicals. It is cell-free, entirely in-house and scaleable with fast turnaround and the ability to produce complex sequences of high purity. Our DNA is suitable for a range of applications, including: DNA templates for mRNA, monoclonal antibodies, personalized medicines and gene therapies.SInce inception the company has built a solid reputation for our flexibility and an innovative approach to complex and challenging projects meaning our products are suitable for a variety of research and product developmental uses by the pharmaceutical industry.

PharmaKrysto was founded by a highly experienced team of drug developers who were inspired to create the company when we understood what people with Cystinuria experience every day and how a new and effective therapy could positively change their lives.Our mission is to save kidneys and prevent pain in the adults and children with this life-changing condition who experience significant mental anguish as well as severe, frequent pain, kidney damage and a risk of kidney failure caused by chronically recurring deposits of large amino acid crystals in their kidneys.We have been working with scientists in the USA who have discovered a method of blocking the growth of cystine crystals, through the use of newly invented molecules which have the potential to become a medication that could be taken as a tablet and prevent the growth of these stones. The IP and technology - for which we have worldwide exclusivity to develop and commercialise - works in a completely different way to current therapies and we are working to turn it into an effective treatment that has none of the drawbacks or severe side effects of current treatments.

In business delivery is key. WIthout delivery value is destroyed and stakeholders quickly become disatisfied and disenfranchised. The primary aim of Livero Partners is to facilitate the effective, timely and value-creating delivery of our clients projects.

At LUNAC Therapeutics we're developing a first-in-class, next generation oral anticoagulant for the treatment and prevention of life-threatening thrombotic events, without the bleeding risk associated with current anticoagulants. This remains a significant health problem and presents a multi-billion dollar oportunity to a company that can develop a technology that can provide better and safer outcomes for the millions of patients affected by these issues on a daily basis.Our focus is on the inhibition of activated Factor XII (FXIIa), a clotting factor enzyme which plays a key role in pathological clot formation (thrombosis) but not in the stemming of bleeding (haemostasis).​LUNAC is a spin-out company from the University of Leeds, founded and supported by world-leading experts in blood coagulation. We have already received over £8m of financial backing from the British Heart Foundation, the Wellcome Trust, Innovate UK, Epidarex Capital and the University of Leeds and are working towards commencing human studies of our tehnology as quickly as possible.Visit www.lunactherapeutics.com for more info.

Gateshead Quays, Gb

Shield Therapeutics plc is a UK-based and publicly-listed pharmaceutical company focused on developing and commercialising novel specialty prescription pharmaceuticals. Shield’s two leading assets are Feraccru®, which is approved in Europe for the treatment of iron deficiency anaemia, and PT20, a treatment for hyperphosphataemia which has successfully completed a 1st pivotal study, leaving one study to be completed before a marketing authorisation application. The company was founded by Carl Sterritt.

Successfully led commercial operations of Encysive's European business until it was acquired by Pfizer. In this role all the country by country operations reported to me and I carried responsiblity for European wide sales targets and associated expense budgets.

Having the backing of leading clinicians, whilst working for United Therapeutics (UT) I proposed to the CEO that we redevelop the Company's lead product (Remodulin), which was formulated for subcutaneous infusion, as an inhaled formulation. After much discussion the CEO agreed to my idea and we started operations as Lung Rx. This division of UT has subsequently gone on to develop this product, which now forms a major part of the perceived value of United Therapeutics' stock price as can be seen by the effective news on the inhaled development has on the company's stock performance. The product has been well received by the scientific community and is currently being assessed by regulatory agencies for marketing authorisation.

Having worked with United Therapeutics on a contract basis through projects at Quintiles, I was approached by one of the founders of UT to set up the company's European operations. Therefore I became the 1st employee of the European company and led the business for 6 years as we grew our operations in this market. By the time I left, the company I had led was very welll respected by competitors and customers in the European PAH market, had enjoyed it's 1st marketing authorisation in Europe, was significantly increasing sales year on year, had signed multiple distribution deals with commercial partners and was beginning to build major infrastructure to use as a base to grow from.

Durham, North Carolina, Us

Instigated and managed multi-national clinical trials of candidate therapeutics

Mba, Business

Msc, Clinical Toxicology

Bsc (Hons), Biochemistry